Regulatory Open Forum

 View Only
  • 1.  What issues are you looking forward to talking about informally when you meet in person again?

    Posted 14-Mar-2022 08:11

    I'm really looking forward to finally meet my regulatory friends live again at Euro Convergence this May.

    For me, the unscheduled corridor and diner talks bring out the best in regulatory intelligence as regulatory friends are out there to share their wisdom and exchange views and intuition.

    What three topics would you raise when meeting in the corridor or over diner?



    ------------------------------
    Gert Bos FRAPS, PhD
    CTO, Executive Director & Partner at Qserve Group
    Baarn
    Netherlands
    Gert.bos@qservegroup.com
    ------------------------------


  • 2.  RE: What issues are you looking forward to talking about informally when you meet in person again?

    Posted 15-Mar-2022 13:01
    My main interest right now is how six designated conformity assessment bodies will be able to surveil a much larger number of IVDs that now need Notified Body involvement. 

    At the rate Notified Bodies are being designated to IVDR (2 per year since the first designation), we won't have all 17 who applied designated until 2027, and this doesn't constitute any increase in Notified Bodies under IVDR vs. IVDD (18 NBs), though we have gone from 10 - 20% of IVDs needing a Notified Body (IVDD) to near 90% (IVDR).

    Even with a progressive roll-out, these numbers seem to make implementation of the IVDR particularly challenging.

    ------------------------------
    Corey Jaseph RAC
    Senior Research Analyst
    Wheatland CA
    United States
    ------------------------------



  • 3.  RE: What issues are you looking forward to talking about informally when you meet in person again?

    Posted 15-Mar-2022 13:08
    Agreed wholeheartedly! 

    Question is not who we blame, but how we solve it. And what can you do to provide focus and priority in any conformity assessment engaged in !

    Outlook voor iOS downloaden
    Kind regards | Met vriendelijke groet | Mit freundlichen Grüßen | Cordialemente | 以此致敬意
    Gert Bos PhD
    Executive Director & Partner | CSO | CEO Qserve China
    T: +31 207 882 630 | M: +31 629 728 051
    E: Gert.Bos@Qservegroup.com | 
    W: www.qservegroup.com
    Qserve Group B.V. | Utrechtseweg 310 ‑ B42 | 6812AR | Arnhem | The Netherlands
    Europe ‑ The Netherlands, Germany, UK & Belgium | USA ‑ Massachusetts & California | China ‑ Nanjing
    Company Video ‑>
    Your Global MedTech Partner for Regulatory, Quality Affairs and Clinical Trials
    The above information is intended only for the person or entity to whom it is addressed and may contain confidential and/or privileged information. Any review, retransmission, 
    dissemination of, or taking action in reliance upon this information by others than the intended recipient is prohibited. If you are not the intended recipient, please return 
    this e‑mail to the sender and delete it from any computer system.





  • 4.  RE: What issues are you looking forward to talking about informally when you meet in person again?

    Posted 16-Mar-2022 18:35
    So let me ask you a question. What is 'draft designation' for a Notified Body? I see it in the MDCG meeting agenda for next Monday, but I have been unable to find anything to elaborate on that agenda item where MDCG is looking for endorsement of this proposal.

    ------------------------------
    Corey Jaseph RAC
    Senior Research Analyst
    Wheatland CA
    United States
    ------------------------------



  • 5.  RE: What issues are you looking forward to talking about informally when you meet in person again?

    Posted 16-Mar-2022 18:44
    Interesting question

    I'd be assuming this agenda item is a final discussion on the status of the next notified body that will be receiving designation  

    Thanks. G

    Outlook voor iOS downloaden
    Kind regards | Met vriendelijke groet | Mit freundlichen Grüßen | Cordialemente | 以此致敬意
    Gert Bos PhD
    Executive Director & Partner | CSO | CEO Qserve China
    T: +31 207 882 630 | M: +31 629 728 051
    E: Gert.Bos@Qservegroup.com | 
    W: www.qservegroup.com
    Qserve Group B.V. | Utrechtseweg 310 ‑ B42 | 6812AR | Arnhem | The Netherlands
    Europe ‑ The Netherlands, Germany, UK & Belgium | USA ‑ Massachusetts & California | China ‑ Nanjing
    Company Video ‑>
    Your Global MedTech Partner for Regulatory, Quality Affairs and Clinical Trials
    The above information is intended only for the person or entity to whom it is addressed and may contain confidential and/or privileged information. Any review, retransmission, 
    dissemination of, or taking action in reliance upon this information by others than the intended recipient is prohibited. If you are not the intended recipient, please return 
    this e‑mail to the sender and delete it from any computer system.